EGFR mutation-positive NSCLC

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:non-small_cell_lung_cancer_subtype
gptkbp:diagnosedBy	molecular testing
gptkbp:hasApprovedDrug	gptkb:afatinib gptkb:erlotinib gptkb:gefitinib gptkb:osimertinib
gptkbp:hasBiomarker	EGFR protein overexpression
gptkbp:hasFirstLineTherapy	gptkb:osimertinib
gptkbp:hasGeneticAlteration	gptkb:EGFR_mutation
gptkbp:hasResistanceMechanism	HER2 amplification MET amplification small cell transformation
gptkbp:hasResistanceMutation	gptkb:T790M_mutation
gptkbp:hasSecondLineTherapy	chemotherapy
gptkbp:hasTargetedTherapy	gptkb:EGFR_tyrosine_kinase_inhibitor
gptkbp:incidence	10-15% in Western populations 30-50% in Asian populations
gptkbp:mutationAssociatedWith	gptkb:L858R_mutation exon 19 deletion
gptkbp:prevalence	gptkb:East_Asian_populations females non-smokers
gptkbp:prognosis	generally better than EGFR wild-type NSCLC
gptkbp:subspecies	gptkb:lung_adenocarcinoma
gptkbp:treatment	gptkb:targeted_therapy chemotherapy immunotherapy (less effective)
gptkbp:bfsParent	gptkb:Tagrisso
gptkbp:bfsLayer	7
https://www.w3.org/2000/01/rdf-schema#label	EGFR mutation-positive NSCLC